Tomita Y, Oronsky B, Abrouk N, Cabrales P, Reid TR, Lee MJ, Yuno A, Baker J, Lee S, Trepel JB.Transl Lung Cancer Res. 2021 Jan;10(1):274-278. doi: 10.21037/tlcr-20-359.PMID: 33569311 Free PMC article.
Journal Publications
RRx-001 Increases Erythrocyte Preferential Adhesion to the Tumor Vasculature.
Jani VP, Asaro R, Oronsky B, Cabrales P.Int J Mol Sci. 2021 Apr 29;22(9):4713. doi: 10.3390/ijms22094713.PMID: 33946824 Free PMC article.
RRx-001 Radioprotection: Enhancement of Survival and Hematopoietic Recovery in Gamma-Irradiated Mice.
Jurgensen KJ, Skinner WKJ, Oronsky B, Abrouk ND, Graff AE, Landes RD, Culp WE, Summers TA Jr, Cary LH.Front Pharmacol. 2021 Apr 22;12:676396. doi: 10.3389/fphar.2021.676396. eCollection 2021.PMID: 33967816 Free PMC article.
An explorary analysis of a COVID-truncated REPLATINUM phase 3 trial in SCLC.
A. Chiappori, M. Fidler, Muhammad A. Salamat, T. Reid, Xiaoning Guo, Xiaohui Wang, Nacer E Abrouk, S. Caroen, Erica Burbano, M. Quinn, Jeannie Williams, R. Hauke Published 2021. Medicine. Journal of Clinical Oncology
RRx-001 ameliorates inflammatory diseases by acting as a potent covalent NLRP3 inhibitor.
Chen Y, He H, Lin B, Chen Y, Deng X, Jiang W, Zhou R.Cell Mol Immunol. 2021 Jun;18(6):1425-1436. doi: 10.1038/s41423-021-00683-y. Epub 2021 May 10.PMID: 33972740
Vascular priming with RRx-001 to increase the uptake and accumulation of temozolomide and irinotecan in orthotopically implanted gliomas.
Oronsky B, Reid T, Cabrales P.J Drug Target. 2021 May 20:1-6. doi: 10.1080/1061186X.2021.1904248. Online ahead of print.PMID: 34016002
Discovery of RRx-001, a Myc and CD47 Downregulating Small Molecule with Tumor Targeted Cytotoxicity and Healthy Tissue Cytoprotective Properties in Clinical Development.
Oronsky B, Guo X, Wang X, Cabrales P, Sher D, Cannizzo L, Wardle B, Abrouk N, Lybeck M, Caroen S, Oronsky A, Reid TR.J Med Chem. 2021 Jun 10;64(11):7261-7271. doi: 10.1021/acs.jmedchem.1c00599. Epub 2021 May 27.PMID: 34043360 Free article.
Inhibition of the Inflammasome Activity of NLRP3 Attenuates HDM-Induced Allergic Asthma.
Ma M, Li G, Qi M, Jiang W, Zhou R. Front Immunol. 2021 Aug 3;12:718779. doi: 10.3389/fimmu.2021.718779. eCollection 2021.PMID: 34413860 Free PMC article.
Six degrees of separation: The oxygen effect in the development of radiosensitizers
Oronsky B, Knox S, Scicinski J. Trans. Onc. 2011, 4, 256
Is nitric oxide (NO) the last word in radiosensitization? A review
Oronsky B, Knox S, Scicinski J. Trans. Onc. 2012, 5, 66
Beyond antiangiogenesis: Vascular modulation as an anticancer therapy-a review
Oronsky B, Scicinski J, Reid T, Knox S. Trans. Onc. 2012, 5, 133
The scarlet letter of alkylation: A mini review of selective alkylating agents
Oronsky B, Reid T, Knox S, Scicinski J. Trans. Onc. 2012, 21, 226
Development of a safe and efficient two-step synthesis for preparing 1-bromoacetyl-3,3-dinitroazetidine, a novel clinical anticancer candidate
Straessler N, Lesley M, Cannizzo L. Org. Process Res. Dev. February 15, 2012, pp 512–517 DOI: 10.1021/op2003216
Episensitization: Therapeutic tumor resensitization by epigenetic agents: A review and reassessment
Oronsky B, Oronsky N, Knox S, Fanger G, Scicinski J. Anti-Cancer Agents in Medicinal Chemistry, 2014, 14, 1187-1198
Follow the ATP: Tumor energy production. a perspective
Oronsky B, Oronsky N, Fanger G, Parker C, Caroen S, Lybeck M, Scicinski J. Anticancer Agents Med Chem 2014;14(9):1187-98
Rewriting the epigenetic code for tumor resensitization: A review
Oronsky B, Oronsky N, Scicinski J, Fanger G, Lybeck M, Reid T. Trans. Onc. 2014, 7, 626-631
The war on cancer: A military perspective
Oronsky B, Carter C, Mackie V, Scicinski J, Oronsky A, Oronsky N, Caroen S, Parker C, Lybeck M, Reid T. Front Oncol. 2014; 4: 387
Episensitization: Defying time’s arrow
Oronsky B, Oronsky A, Lybeck M, Oronsky N, Scicinski J, Carter C, Day R, Rodriguez Orengo J, Rodriguez-Torres M, Fanger G, Reid T. Front Oncol. 2015 Jun 11;5:134
Going viral: A review of replication-selective oncolytic adenoviruses.
Larson C, Oronsky B, Scicinski J, Fanger G, Stirn M, Oronsky A, Reid T. Oncotarget. 2015 Aug 21;6(24):19976-89.
Confirmatory trials in the evaluation of anticancer medicinal products in man—PFS2: A measure of therapeutic action-at-a-distance
Oronsky B, Carter C, Reid T, Scicinski J, Oronsky A, Lybeck M, Caroen S, Stirn M, Oronsky N, Langecker P Neoplasia 2015, 17(9): 716-722
Addressing the elephant in the room, therapeutic resistance in non-small cell lung cancer, with epigenetic therapies
Carter C, Zeman K, Day R, Richard P, Oronsky A, Oronsky N, Lybeck M, Scicinski J, Oronsky B. Oncotarget. 2016 Mar 19.
Rockets, radiosensitizers, and RRx-001: An origin story part I
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Discov Med. 2016 Mar;21(115):173-80.
RRx-001, a novel dinitroazetidine radiosensitizer
Oronsky B, Scicinski J, Ning S, Peehl D, Oronsky A, Cabrales P, Bednarski M, Knox S. Invest New Drugs. 2016 Jun;34(3):371-7.
“No patient left behind”: An alternative to “the war on cancer” metaphor
Oronsky B, Carter C, Oronsky A, Salacz M, Reid T. Med Oncol. 2016 Jun;33(6):55.
Turning on the radio: Epigenetic inhibitors as potential radiopriming agents.
Oronsky B, Scicinski J, Kim M, Cabrales P, Salacz M, Carter C, Oronsky N, Lybeck H, Lybeck M, Larson C, Reid T, Oronsky A. Biomolecules. 2016 Jul 4;6(3). pii: E32. doi: 10.3390/biom6030032.
RRx-001: A systemically non-toxic M2-to-M1 macrophage stimulating and prosensitizing agent in phase II clinical trials.
Oronsky B, Paulmurugan R, Foygel K, Scicinski J, Knox S, Peehl D, Zhao H, Ning S, Cabrales P, Summers T Jr, Reid T, Fitch W, Kim M, Trepel J, Lee M, Kesari S, Abrouk N, Day R, Oronsky A, Ray C, Carter C. Expert Opin Investig Drugs. 2017 Jan;26(1):109-119. doi:...
A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer.
Oronsky B, Ray C, Spira A, Trepel JB, Carter C, Cottrill H. Med Oncol. 2017 Jun;34(6):103. doi: 10.1007/s12032-017-0960-z. Epub 2017 Apr 25.
No patient left behind: The promise of immune priming with epigenetic agents.
Carter C, Oronsky B, Roswarski J, Oronsky A, Oronsky N, Scicinski J, Lybeck H, Kim M, Lybeck M, Reid T. Oncoimmunology. 2017 Aug 30;6(10):e1315486. doi: 10.1080/2162402X.2017.1315486. eCollection 2017.
Nitric oxide donor-based cancer therapy: advances and prospects
Huang Z, Fu J, Zhang Y. J Med Chem. 2017 Sep 28 doi: 10.1021/acs.jmedchem.6b01672.
What’s new in SCLC? A review.
Oronsky B, Reid T, Oronsky A, Carter C. Neoplasia. 2017 Oct;19(10):842-847. doi: 10.1016/j.neo.2017.07.007. Epub 2017 Sep 6.
Electrolyte disorders with platinum-based chemotherapy: Mechanisms, manifestations and management.
Oronsky B, Caroen S, Oronsky A, Dobalian V, Oronsky N, Lybeck M, Reid T, Carter C. Cancer Chemother Pharmacol. 2017 Nov;80(5):895-907. doi: 10.1007/s00280-017-3392-8. Epub 2017 Jul 20.
Nothing but NET: A review of neuroendocrine tumors and carcinomas.
Oronsky B, Ma P, Morgensztern D, Carter C. Neoplasia. 2017 Dec;19(12):991-1002. doi: 10.1016/j.neo.2017.09.002. Epub 2017 Nov 5.
A review of clinical radioprotection and chemoprotection for oral mucositis
Oronsky B, Burbano E, Kim M, Oronsky N, Lybeck M, Goyal S, Cabrales P, Caroen S, Oronsky A, Carter C. Translational Oncology. Apr 2018.
A practical guide to the handling and administration of personalized transcriptionally attenuated oncolytic adenoviruses (PTAVs)
Larson C, Oronsky B, Varner G, Caroen S, Burbano E, Insel E, Hedjran F, Carter C, Reid T. OncoImmunology, 2018, Jul 23.
Two case reports of resensitization to previous chemotherapy with the novel hypoxia-activated hypomethylating anticancer agent RRx-001 in metastatic colorectal cancer patients
Reid T, Dad S, Korn R, Oronsky B, Knox S, Scicinski J. Case Rep Oncol. 2014 Jan 24;7(1):79-85. doi: 10.1159/000358382.
Dysphonia after bevacizumab rechallenge: A case report.
Carter C, Caroen S, Oronsky A, Oronsky B. Case Rep Oncol. 2015 Oct 14;8(3):423-5. doi: 10.1159/000441122. eCollection 2015 Sep-Dec.
Flushing out carcinoid syndrome: Beneficial effect of the anticancer epigenetic agent RRx-001 in a patient with a treatment-refractory neuroendocrine tumor
Carter C, Degesys A, Oronsky B, Scicinski J, Caroen S, Oronsky A, Reid T, Cabrales P, Roswarski J. Case Rep Oncol. 2015 Oct 30;8(3):461-5.
RRx-001-induced tumor necrosis and immune cell Infiltration in an EGFR mutation-positive NSCLC with resistance to EGFR tyrosine kinase inhibitors: A case report
Brzezniak C, Schmitz B, Peterson P, Degesys A, Oronsky B, Scicinski J, Caroen S, Carter C. Case Rep Oncol. 2016 Jan 15;9(1):45-50.
The case of a zebra that was misdiagnosed as a horse: Pulmonary tumor thrombotic microangiopathy, a new paraneoplastic syndrome, mimicking PD-1-Induced pneumonitis
Carter C, Browning R, Oronsky B, Scicinski J, Brzezniak C. Case Rep Oncol. 2016 Jan 27;9(1):68-75.
Partial response to platinum doublets in refractory EGFR-positive non-small cell lung cancer patients after RRx-001: Evidence of episensitization
Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Reid T, Degesys A, Jenkins J, Brzezniak C. Case Rep Oncol. 2016 Jan 28;9(1):62-7.
Immune reactivity and pseudoprogression or tumor flare in a serially biopsied neuroendocrine patient treated with the epigenetic agent RRx-001
Carter C, Schmitz B, Peterson P, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid T, Cabrales P, Brzezniak C. Case Rep Oncol. 2016 Mar 10;9(1):164-70.
RRx-001 in refractory small-cell lung carcinoma: A case report of a partial response after a third reintroduction of platinum doublets.
Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Kim M, Oronsky A, Lybeck H, Cabrales P, Oronsky N, Reid T, Roswarski J, Brzezniak C. Case Rep Oncol. 2016 Mar 11;9(1):171-6. doi: 10.1159/000444631. eCollection 2016 Jan-Apr.
Concurrent whole brain radiotherapy and RRx-001 for melanoma brain metastases
Kim M, Parmar H, Cao Y, Knox S, Oronsky B, Scicinski J, Lawrence T, Lao C. Neuro Oncol. 2016 Mar;18(3):455-6.
Whole brain radiotherapy and RRx-001: Two partial responses in radioresistant melanoma brain metastases from a phase I/II clinical trial: A TITE-CRM phase I/II clinical trial
Kim M, Parmar H, Cao Y, Pramanik P, Schipper M, Hayman J, Junck L, Mammoser A, Heth J, Carter C, Oronsky A, Knox S, Caroen S, Oronsky B, Scicinski J, Lawrence T, Lao C. Transl Oncol. 2016 Apr;9(2):108-13.
Pulmonary tumor thrombotic microangiopathy: A new paraneoplastic syndrome?
Carter C, Scicinski J, Lybeck H, Oronsky B. Case Rep Oncol. 2016 Apr 23;9(1):246-8.
Partial response to carboplatin in an RRx-001 pretreated patient with EGFR-inhibitor-resistance and T790M-negative NSCLC
Carter C, Oronsky B, Caroen S, Scicinski J, Cabrales P, Degesys A, Brzezniak C. Respir Med Case Rep. 2016 Apr 24;18:62-5.
Partial response in an RRx-001 primed patient with refractory small-cell lung cancer after a third introduction of platinum doublets.
Carter C, Oronsky B, Caroen S, Scicinski J, Degesys A, Cabrales P, Reid T, Brzezniak C. Case Rep Oncol. 2016 May 24;9(2):285-9. doi: 10.1159/000446209. eCollection 2016 May-Aug.
Conversion of platinum-etoposide-resistant to sensitive SCLC after treatment with the epi-immunotherapeutic RRx-001: A case report.
Brzezniak C, Oronsky B, Scicinski J, Caroen S, Cabrales P, Dean Abrouk N, Kim M, Brown J, Reid T, Larson C, Oronsky A, Day R, Degesys A, Carter C. Oncol Res Treat. 2016;39(11):720-723. Epub 2016 Sep 19.
A partial response to reintroduced chemotherapy in a resistant small cell lung cancer patient after priming with RRx-001.
Oronsky B, Caroen S, Zeman K, Quinn M, Brzezniak C, Scicinski J, Cabrales P, Reid T, Trepel J, Abrouk N, Larson C, Oronsky A, Lybeck H, Day R, Carter C. Clin Med Insights Oncol. 2016 Nov 6;10:105-108. eCollection 2016.
RRx-001 priming of PD-1 inhibition in the treatment of small cell carcinoma of the vagina: A rare gynecological tumor.
Brzezniak C, Oronsky B, Trepel J, Summers T Jr, Cabrales P, Lee M, Day R, Jha S, Caroen S, Zeman K, Ferry L, Harmer C, Oronsky N, Lybeck M, Lybeck H, Brown J, Reid T, Carter C. Case Rep Oncol. 2017 Mar 29;10(1):276-280. doi: 10.1159/000464101. eCollection 2017 Jan-Apr.